7 Undervalued Biotechnology Stocks for Thursday, October 31
Discover the top 7 undervalued Biotechnology stocks for Thursday, October 31 based on AAII’s Stock Grades.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Commentary & Analysis
6 Undervalued Pharmaceuticals Stocks for Monday, September 02
Discover the top 6 undervalued Pharmaceuticals stocks for Monday, September 02 based on AAII’s Stock Grades.Eunice Kim
5 Undervalued Pharmaceuticals Stocks for Friday, April 07
Discover the top 5 undervalued Pharmaceuticals stocks for Friday, April 07 based on AAII’s Stock Grades.Cynthia McLaughlin
4 Undervalued Pharmaceuticals Stocks for Tuesday, January 31
Discover the top 4 undervalued Pharmaceuticals stocks for Tuesday, January 31 based on AAII’s Stock Grades.Cynthia McLaughlin
Is Silo Pharma Inc (SILO) Stock a Good Investment?
Learn more about Silo Pharma Inc's (SILO) stock grades for Value, Momentum and Growth and determine whether this Pharmaceuticals stock meets your investment needs.Jack Gilleland
Financial Summary
| Share Statistics | SILO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.9 | $218.1 | 1% |
|
| Shares Out (Mil) | 1.1 | 53.9 | 5% |
|
| Institutional Ownership | 91.4% | 93.1% | 60% |
|
| Float (Mil) | 1.6 | 40.9 | 4% |
|
| Beta | 0.80 | 0.95 | 47% |
|
| Avg Daily Volume (000s) | 173 | 611 | 43% |
|
| Price Change (52-week) |
(87.3%) | 46.3% | 6% |
|
| Growth | SILO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (7.0%) | (10.2%) | 32% |
|
| EPS (5yr) | 28.9% | 15.7% | 80 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (33.4%) | (15.7%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SILO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($5) | ($44) | 34% |
|
| EPS (TTM) | ($5.067) | ($1.600) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($33) | 27% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($1) | $177 | 3% |
|
| Valuation | SILO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.28 | 2.13 | 5% |
|
| P/E | na | 19.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SILO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (14.8%) | 66.0% | 3% |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (71.0%) | (47.2%) | 8% |
|
| ROE | (91.2%) | (54.2%) | 10% |
|
| Liabilities to Assets | 17.9% | 29.1% | 11% |
|
| F-Score | 1 | 3 | 1% |
|
Passing Stock Screens
As of 10/14/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Schloss Screen
Factors: Value, Quality
This screen looks for stocks hitting new lows, trading at a price lower than book value per share, with no debt and high levels of insider ownership.
| Performance Since Inception: | 3.6% |
| +/- S&P 500: | -3.9 |
